Coya Therapeutics Files $75 Million Mixed Shelf and Reports Q2 Earnings

Coya Therapeutics has filed a $75 million mixed shelf offering. The company also reported earnings results for the second quarter and six months ended June 30, 2025. Additionally, the FDA has been unable to meet the review goal date for Coya's IND for a phase 2 ALS study. Coya has announced updates on its investigational new drug application and publication of scientific research linking inflammation and oxidative stress to Parkinson's disease progression.

Houston, TX - Coya Therapeutics, Inc. (NASDAQ: COYA) has recently filed a $75 million mixed shelf offering, which includes both common stock and warrants. The company also reported its earnings results for the second quarter and six months ended June 30, 2025. Additionally, Coya Therapeutics announced that the FDA has been unable to meet the review goal date for the company's investigational new drug (IND) application for a phase 2 ALS study. The company also provided updates on its IND application and published scientific research linking inflammation and oxidative stress to Parkinson's disease progression.

In the second quarter, Coya Therapeutics reported a cash balance of $29.8 million. The company's collaboration revenues for the quarter were $0.2 million, a significant decrease from the previous quarter's $3.4 million. The decrease was primarily due to the immediate recognition of license revenue upon executing the First Amendment to the DRL Development Agreement during the previous quarter. Research and development expenses for the quarter amounted to $3.7 million.

The company has been actively engaged in various research activities, including the publication of scientific research linking inflammation and oxidative stress to the progression of Parkinson's disease. Additionally, Coya Therapeutics has announced updates on its IND application and the publication of scientific research linking inflammation and oxidative stress to Parkinson's disease progression.

Despite the challenges faced by the company, Coya Therapeutics remains optimistic about its future prospects. The company's Chief Executive Officer, Arun Swaminathan, Ph.D., commented, "As we look ahead, we are focused on several key catalysts, including a decision from the FDA on our IND application for COYA 302 in ALS, anticipated by the end of August. We are encouraged by the growing body of data supporting our regulatory T cell enhancement approach, including the recent findings from the investigator-initiated trial in FTD and promising pre-clinical results with COYA 303. These advances strengthen our confidence in the potential of COYA 302 in neurodegenerative diseases like ALS and FTD."

The upcoming earnings report is expected to provide further insights into the company's financial performance and its strategic initiatives. The market sentiment appears to be cautiously optimistic, driven by the company's promising product pipeline and strategic partnerships.

References:
[1] https://www.marketscreener.com/news/coya-therapeutics-files-75-million-mixed-shelf-ce7c51dada8df723
[2] https://www.ainvest.com/news/coya-therapeutics-coya-q2-2025-earnings-preview-upside-potential-promising-product-pipeline-2508/
[3] https://finance.yahoo.com/news/coya-therapeutics-reports-second-quarter-120000046.html